Trials / Completed
CompletedNCT01707394
Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder
Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 1 Day – 18 Years
- Healthy volunteers
- Not accepted
Summary
CV185118 is a single dose Apixaban PK/PD study in pediatric participants. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric participants at risk for thrombosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apixaban | Specified dose on specified days |
Timeline
- Start date
- 2013-01-10
- Primary completion
- 2020-06-30
- Completion
- 2020-06-30
- First posted
- 2012-10-16
- Last updated
- 2021-03-22
Locations
27 sites across 5 countries: United States, Australia, Canada, Israel, Mexico
Source: ClinicalTrials.gov record NCT01707394. Inclusion in this directory is not an endorsement.